Clinical Research Directory

Inclusion Criteria: 1. The decision of treating physicians to make cR2 regimen was not related to whether they participated in the study or not; 2. Age 18 and above, no gender limitation; 3. Patients with pathologically confirmed diffuse large B-cell lymphoma (DLBCL) who have relapsed or failed to respond to at least one systemic therapy; 4. Have at least one measurable lesion: any length of lymph node lesion ≥1.5cm or any length of extrinsic lesion \> 1cm; 5. The serum pregnancy test of female subjects of childbearing age was negative; 6. Understand the test procedure and content, and sign the informed consent voluntarily. Exclusion Criteria: 1. The decision of treating physicians to make cR2 regimen was not related to whether they participated in the study or not; 2. Age 18 and above, no gender limitation; 3. Patients with pathologically confirmed diffuse large B-cell lymphoma (DLBCL) who have relapsed or failed to respond to at least one systemic therapy; 4. Have at least one measurable lesion: any length of lymph node lesion ≥1.5cm or any length of extrinsic lesion \> 1cm; 5. The serum pregnancy test of female subjects of childbearing age was negative; 6. Understand the test procedure and content, and sign the informed consent voluntarily.